EX-10.27





 Exhibit 10.27 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I)
NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

  
 



 
 GRANT AGREEMENT 

Investment ID OPP1182112 

AGREEMENT SUMMARY & SIGNATURE PAGE 
  

			
	GRANTEE INFORMATION
		
	Name:	  	Vir Biotechnology, Inc.
		
	Tax Status:	  	 Not exempt from federal income tax under U.S. IRC § 501(c)(3)

You confirm that the above information is correct and agree to notify the Foundation immediately of any change.

		
	Expenditure Responsibility:	  	This Agreement is subject to “expenditure responsibility” requirements under the U.S. Internal Revenue Code.
		
	Mailing Address:	  	 499 Illinois Street, Suite 500
 San Francisco,
CA 94158
 United States

		
	Primary Contact:	  	[***]

  

			
	FOUNDATION INFORMATION
		
	Mailing Address:	  	P. O. Box 23350, Seattle, WA 98102, U.S.A.
		
	Primary Contact:	  	[***]

  

			
	AGREEMENT INFORMATION
		
	Title:	  	Development of a CMV-TB vaccine
		
	“Charitable Purpose”:	  	To develop a safe and effective TB vaccine to benefit low-income countries where the disease is most prevalent
		
	“Start Date”:	  	Date of last signature
		
	“End Date”:	  	June 30, 2020
		
	This Agreement includes and incorporates by this reference:	  	 This Agreement Summary & Signature Page and:
  

•  Grant Amount and Reporting & Payment Schedule (Attachment A)

 
 •  Terms and Conditions
(Attachment B)
  
 •  Proposal
Narrative (date submitted January 31, 2018)
  

•  Results Framework and Tracker (date submitted December 15. 2017)

 
 •  Budget (date submitted
January 31, 2018)


 THIS AGREEMENT is between Vir Biotechnology Inc (“You” or “Grantee”) and the
Bill & Melinda Gates Foundation (“Foundation”), and is effective as of the date of last signature. Each party to this Agreement may be referred to individually as a “Party” and together as the
“Parties.” As a condition of this grant, the Parties enter into this Agreement by having their authorized representatives sign below. 
  

					
	BILL & MELINDA GATES FOUNDATION	  		  	VIR BIOTECHNOLOGY INC
			
	 /s/ Trevor Mundel

By: Trevor Mundel
 Title: President, Global Health
	  		  	 /s/ Michael Kamarck

By: Michael Kamarck
 Title: Chief Technology Officer

			
	 March 15, 2018

Date
	  		  	 March 16, 2018

Date


  












 GRANT AGREEMENT 

Investment ID OPP1182112 

ATTACHMENT A 
 GRANT
AMOUNT AND REPORTING & PAYMENT SCHEDULE 
 GRANT AMOUNT 

The Foundation will pay You up to the total grant amount specified in the Reporting & Payment Schedule below. The Foundation’s Primary Contact
must approve in writing any Budget cost category change of more than [***]. 
 REPORTING & PAYMENT SCHEDULE 

Payments are subject to Your compliance with this Agreement, including Your achievement, and the Foundation’s approval, of any applicable targets,
milestones, and reporting deliverables required under this Agreement. The Foundation may, in its reasonable discretion, modify payment dates or amounts and will notify You of any such changes in writing. 

REPORTING 
 You will submit reports according to the
Reporting & Payment Schedule using the Foundation’s templates or forms, which the Foundation will make available to You and which may be modified from time to time. For a progress or final report to be considered satisfactory, it
must demonstrate meaningful progress against the targets or milestones for that investment period. If meaningful progress has not been made, the report should explain why not and what adjustments You are making to get back on track. Please notify
the Foundation’s Primary Contact if You need to add or modify any targets or milestones. The Foundation must approve any such changes in writing. You agree to submit other reports the Foundation may reasonably request. 

ACCOUNTING FOR PERSONNEL TIME 
 You will track the time of
all employees, contingent workers, and any other individuals whose compensation will be paid in whole or in part by Grant Funds. Such individuals will keep records (e.g., timesheets) of actual time worked on the Project in increments of sixty
minutes or less and brief descriptions of tasks performed. You will report actual time worked consistent with those records in Your progress and final budget reports. You will submit copies of such records to the Foundation upon request. 

  
 Page 2 of 8 














									
	REPORTING & PAYMENT SCHEDULE
					
	 Investment Period
	  	 Target, Milestone,
or Reporting
Deliverable
	  	 Due By
	  	 Payment Date
	  	 Payment Amount (U.S.$)

		  	[***]	  		  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	Up to [***]
	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	Up to [***]
	  	[***]
	 [***]
	  	[***]	  	[***]	  		  	
	  	[***]
		  	  

	Total Grant Amount	  	Up to $14,882,418.08
		  	  



  
 Page 3 of 8 













 GRANT AGREEMENT 

Investment ID OPP1182112 

ATTACHMENT B 

TERMS & CONDITIONS 
 This Agreement is
subject to the following terms and conditions. 
  

	
	PROJECT SUPPORT

 PROJECT DESCRIPTION AND CHARITABLE PURPOSE 

The Foundation is awarding You this grant to carry out the project described in the Proposal Narrative and Results Framework and Tracker
(collectively, “Project”) in order to further the Charitable Purpose. The Foundation, in its discretion, may approve in writing any request by You to make non-material changes to the Proposal
Narrative and/or Results Framework and Tracker. 
  

	
	MANAGEMENT OF FUNDS

 USE OF FUNDS 

You may not use funds provided under this Agreement (“Grant Funds”) for any purpose other than the Project. You may not use
Grant Funds to reimburse any expenses You incurred prior to the Start Date. At the Foundation’s request, You will repay any portion of Grant Funds and/or Income used or committed in material breach of this Agreement, as determined by the
Foundation in its discretion. 
 INVESTMENT OF FUNDS 

You must invest Grant Funds in highly liquid investments with the primary objective of preservation of principal (e.g., interest-bearing bank
accounts or a registered money market mutual fund) so that the Grant Funds are available for the Project. Together with any progress or final reports required under this Agreement, You must report the amount of any currency conversion gains (or
losses) and the amount of any interest, or other income generated by the Grant Funds (collectively, “Income”). Any Income must be used for the Project. 

SEGREGATION OF FUNDS 
 You
must maintain Grant Funds in a physically separate bank account or a separate bookkeeping account maintained as part of Your financial records and dedicated to the Project. 
  

	
	GLOBAL ACCESS

 GLOBAL ACCESS COMMITMENT 

You will conduct and manage the Project and the Funded Developments in a manner that ensures Global Access. Your Global Access commitments will
survive the term of this Agreement. “Funded Developments” means the products, services, processes, technologies, materials, software, data, other innovations, and intellectual property resulting from the Project (including
modifications, improvements, and further developments to Background Technology). “Background Technology” means any and all products, services, processes, technologies, materials, software, data, or other innovations, and intellectual
property created by You or a third party prior to or outside of the Project used as part of the Project. “Global Access” means: (a) the knowledge and information gained from the Project will be promptly and broadly
disseminated; and (b) the Funded Developments will be made available and accessible at an affordable price (i) to people most in need within developing countries, or (ii) in support of the U.S. educational system and public libraries,
as applicable to the Project. 
 PUBLICATION 

Consistent with Your Global Access commitments, if the Project description specifies Publication or Publication is otherwise requested by the
Foundation, You will seek prompt Publication of any Funded Developments consisting of data and results. “Publication” means publication in a peer-reviewed journal or other method of public dissemination specified in the Project
description or otherwise approved by the Foundation in writing. Publication may be delayed for a reasonable period for the sole purpose of seeking patent protection, provided the patent application is drafted, filed, and managed in a manner that
best furthers Global Access. If You seek Publication in a peer-reviewed journal, such Publication shall be under 

  
 Page 4 of 8 













 
“open access” terms and conditions consistent with the Foundation’s Open Access Policy available at:
www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy, which may be modified from time to time. Nothing in this section shall be construed as
requiring Publication in contravention of any applicable ethical, legal, or regulatory requirements. You will mark any Funded Development subject to this clause with the appropriate notice or attribution, including author, date and copyright (e.g., © 20<> <Name>). 
 INTELLECTUAL PROPERTY REPORTING 

During the term of this Agreement and for 5 years after, You will submit upon request annual intellectual property reports related to the
Funded Developments, Background Technology, and any related agreements using the Foundation’s templates or forms, which the Foundation may modify from time to time. 
  

	
	SUBGRANTS AND SUBCONTRACTS

 SUBGRANTS AND SUBCONTRACTS 

Provided that You do not make subgrants to individuals under this Agreement, You have the exclusive right to select subgrantees and
subcontractors to assist with the Project. If You use Grant Funds to make a subgrant to an organization that is not a U.S. public charity or government agency/instrumentality, You must comply with the expenditure responsibility procedures
available at: www.gatesfoundation.org/Documents/Expenditure%20Responsibility%20Procedures%20for%20Subgrants.docx. 

RESPONSIBILITY FOR OTHERS 

You are responsible for (a) all acts and omissions of any of Your trustees, directors, officers, employees, subgrantees, subcontractors,
contingent workers, agents, and affiliates assisting with the Project, and (b) ensuring their compliance with the terms of this Agreement. 
  

	
	PROHIBITED ACTIVITIES

 ANTI-TERRORISM 

You will not use funds provided under this Agreement, directly or indirectly, in support of activities (a) prohibited by U.S. laws
relating to combating terrorism; (b) with persons on the List of Specially Designated Nationals (www.treasury.gov/sdn) or entities owned or controlled by such persons; or (c) in or with countries or territories against which
the U.S. maintains comprehensive sanctions (currently, Cuba, Iran, Syria, North Korea, and the Crimea Region of Ukraine), including paying or reimbursing the expenses of persons from such countries or territories, unless such activities are fully
authorized by the U.S. government under applicable law and specifically approved by the Foundation in its sole discretion. 

ANTI-CORRUPTION; ANTI-BRIBERY 

You will not offer or provide money, gifts, or any other things of value directly or indirectly to anyone in order to improperly influence
any act or decision relating to the Foundation or the Project, including by assisting any party to secure an improper advantage. Training and information on compliance with these requirements are available at www.learnfoundationlaw.org. 

POLITICAL ACTIVITY AND ADVOCACY 

You may not use Grant Funds to influence the outcome of any election for public office or to carry on any voter registration drive. You may not
use Grant Funds to support lobbying activity or to otherwise support attempts to influence local, state, federal, or foreign legislation. Your strategies and activities, and any materials produced with Grant Funds, must comply with applicable local,
state, federal, or foreign lobbying law. You agree to comply with lobbying, gift, and ethics rules applicable to the Project. 
  

	
	PUBLICITY

 PUBLICITY BY THE FOUNDATION 

The Foundation may include information about the award of this grant, including Your name, in its periodic public reports and may make such
information available on its website and as part of press releases, public reports, speeches, newsletters, tax returns, and other public disclosures. 

  
 Page 5 of 8 













 PUBLICITY BY YOU 

You must obtain the Foundation’s prior written approval before: (a) issuing a press release or other public announcement regarding
this grant; and (b) any other public use of the Foundation’s name or logo. Please email Your request to: grantee.comms@gatesfoundation.org two weeks in advance to provide the Foundation an opportunity to review and comment. Detailed
guidelines are available at: 
 www.gatesfoundation.org/grantseeker/documents/guidelines communications for grantees.doc. 

PUBLICITY BY OTHERS 
 You
and Your subgrantees, subcontractors, contingent workers, agents, or affiliates may not state or otherwise imply to third parties that the Foundation directly funds or otherwise endorses their activities. 

 

	
	OTHER

 COMPLIANCE WITH LAWS 

In carrying out the Project, You will comply with all applicable laws, regulations, and rules and will not infringe, misappropriate, or violate
the intellectual property, privacy, or publicity rights of any third party. 
 COMPLIANCE WITH REQUIREMENTS 

You will conduct, control, manage, and monitor the Project in compliance with all applicable ethical, legal, regulatory, and safety
requirements, including applicable international, national, local, and institutional standards (“Requirements”). You will obtain and maintain all necessary approvals, consents, and reviews before conducting the applicable activity.
As a part of Your annual progress report to the Foundation, You must report whether the Project activities were conducted in compliance with all Requirements. 

If the Project involves: 
 a. any
protected information (including personally identifiable, protected health, or third-party confidential), You will not disclose this information to the Foundation without obtaining the Foundation’s prior written approval and all necessary
consents to disclose such information; 
 b. children or vulnerable subjects, You will obtain any necessary consents and approvals unique to
these subjects; and/or 
 c. any trial involving human subjects, You will adhere to current Good Clinical Practice as defined by the
International Council on Harmonisation (ICH) E-6 Standards (or local regulations if more stringent) and will obtain applicable trial insurance. 

Any activities by the Foundation in reviewing documents and providing input or funding does not modify Your responsibility for determining and
complying with all Requirements for the Project. 
 RELIANCE 

You acknowledge that the Foundation is relying on the information You provide in reports and during the course of any due diligence conducted
prior to the Start Date and during the term of this Agreement. You represent that the Foundation may continue to rely on this information and on any additional information You provide regarding activities, progress, and Funded Developments. 

INDEMNIFICATION 
 If the
Project involves clinical trials, trials involving human subjects, post-approval studies, field trials involving genetically modified organisms, experimental medicine, or the provision of medical/health services (“Indemnified
Activities”), You will indemnify, defend, and hold harmless the Foundation and its trustees, employees, and agents (“Indemnified Parties”) from and against any and all demands, claims, actions, suits, losses, damages
(including property damage, bodily injury, and wrongful death), arbitration and legal proceedings, judgments, settlements, or costs or expenses (including reasonable attorneys’ fees and expenses) (collectively, “Claims”)
arising out of or relating to the acts or omissions, actual or alleged, of You or Your employees, subgrantees, subcontractors, contingent workers, agents, and affiliates with respect to the Indemnified Activities. You agree that any activities by
the Foundation in connection with the Project, such as its review or proposal of suggested modifications to the Project, will not modify or waive the Foundation’s rights under this paragraph. An Indemnified Party may, at its own expense, employ
separate counsel to monitor and participate in the defense of any Claim. Your indemnification obligations are limited to the extent permitted or precluded under applicable federal, state or local laws, including federal or state tort claims
acts, the Federal Anti-Deficiency Act, state governmental immunity acts, or state constitutions. Nothing in this Agreement will constitute an express or implied waiver of Your governmental and sovereign immunities, if any. 

  
 Page 6 of 8 













 INSURANCE 

You will maintain insurance coverage sufficient to cover the activities, risks, and potential omissions of the Project in accordance with
generally-accepted industry standards and as required by law. You will ensure Your subgrantees and subcontractors maintain insurance coverage consistent with this section. 
  

	
	TERM AND TERMINATION

 TERM 

This Agreement commences on the Start Date and continues until the End Date, unless terminated earlier as provided in this Agreement. The
Foundation, in its discretion, may approve in writing any request by You for a no-cost extension, including amending the End Date and adjusting any affected reporting requirements. 

TERMINATION 
 The
Foundation may modify, suspend, or discontinue any payment of Grant Funds or terminate this Agreement if: (a) the Foundation is not reasonably satisfied with Your progress on the Project; (b) there are significant changes to Your
leadership or other factors that the Foundation reasonably believes may threaten the Project’s success; (c) there is a change in Your control; (d) there is a change in Your tax status; or (e) You fail to comply with this
Agreement. 
 RETURN OF FUNDS 

Any Grant Funds, plus any Income, that have not been used for, or committed to, the Project upon expiration or termination of this
Agreement, must be returned promptly to the Foundation. 
 MONITORING, REVIEW, AND AUDIT 

The Foundation may monitor and review Your use of the Grant Funds, performance of the Project, and compliance with this Agreement, which may
include onsite visits to assess Your organization’s governance, management and operations, discuss Your program and finances, and review relevant financial and other records and materials. In addition, the Foundation may conduct audits,
including onsite audits, at any time during the term of this Agreement, and within four years after Grant Funds have been fully spent. Any onsite visit or audit shall be conducted at the Foundation’s expense, following prior written
notice, during normal business hours, and no more than once during any 12-month period. 

INTERNAL OR THIRD PARTY AUDIT 

If during the term of this Agreement You are audited by your internal audit department or by a third party, You will provide the audit report
to the Foundation upon request, including the management letter and a detailed plan for remedying any deficiencies observed (“Remediation Plan”). The Remediation Plan must include (a) details of actions You will take to correct any
deficiencies observed, and (b) target dates for successful completion of the actions to correct the deficiencies. 
 RECORD KEEPING

 You will maintain complete and accurate accounting records and copies of any reports submitted to the Foundation relating to the
Project. You will retain such records and reports for 4 years after Grant Funds have been fully spent. At the Foundation’s request, You will make such records and reports available to enable the Foundation to monitor and evaluate how Grant
Funds have been used or committed. 
 SURVIVAL 

A Party’s obligations under this Agreement will be continuous and survive expiration or termination of this Agreement as expressly
provided in this Agreement or otherwise required by law or intended by their nature. 
  

	
	GENERAL

 ENTIRE AGREEMENT AND AMENDMENTS 

This Agreement contains the entire agreement of the Parties and supersedes all prior and contemporaneous agreements concerning its subject
matter. Except as specifically permitted in this Agreement, no modification, amendment, or waiver of any provision of this Agreement will be effective unless in writing and signed by authorized representatives of both Parties. 

  
 Page 7 of 8 













 NOTICES AND APPROVALS 

Written notices, requests, and approvals under this Agreement must be delivered by mail or email to the other Party’s primary contact
specified on the Agreement Summary & Signature Page, or as otherwise directed by the other Party. 
 SEVERABILITY 

Each provision of this Agreement must be interpreted in a way that is enforceable under applicable law. If any provision is held unenforceable,
the rest of the Agreement will remain in effect. 
 ASSIGNMENT 

You may not assign, or transfer by operation of law or court order, any of Your rights or obligations under this Agreement without the
Foundation’s prior written approval. This Agreement will bind and benefit any permitted successors and assigns. 
 COUNTERPARTS AND
ELECTRONIC SIGNATURES 
 Except as may be prohibited by applicable law or regulation, this Agreement and any amendment may be signed in
counterparts, by facsimile, PDF, or other electronic means, each of which will be deemed an original and all of which when taken together will constitute one agreement. Facsimile and electronic signatures will be binding for all purposes. 

  
 Page 8 of 8